Accustem Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACUT research report →
Price Chart
About the company
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer.
- CEO
- Wendy E. Blosser
- IPO
- 2022
- Employees
- 4
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ACUT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.37M
- P/E
- -1.39
- PEG
- -0.17
- P/S
- 24.08
- P/B
- -0.58
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1780.03%
- Net Margin
- -1680.03%
- ROE
- 46.23%
- ROIC
- 43.20%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-418+88.5%
- Op Income
- $-1,756,096
- Net Income
- $-1,756,096-16.7%
- EPS
- $-0.12+7.7%
- OCF Growth
- -28.1%
- FCF Growth
- -28.1%
- 52W High
- $1.67
- 52W Low
- $0.12
- 50D MA
- $0.16
- 200D MA
- $0.32
- Beta
- 1.87
- RSI (14)
- 53
- Avg Volume
- 2.83K
No earnings-call transcripts are available for ACUT yet.
- Free Float
- 60.8%
- Shares Outstanding
- 16.07M
- Float Shares
- 9.77M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 30, 22 | CERRONE GABRIELE M | buy | 5,000 |
| Dec 2, 22 | CERRONE GABRIELE M | buy | 3,729 |
| Nov 18, 22 | CERRONE GABRIELE M | buy | 24,500 |
| Aug 1, 22 | CERRONE GABRIELE M | buy | 10,000 |
| Jun 8, 22 | CERRONE GABRIELE M | buy | 20,000 |
| Apr 25, 22 | CERRONE GABRIELE M | buy | 4,181 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACUT coverage
Recent articles, reports, and earnings notes.
No research on ACUT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACUT report →AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
globenewswire.com · Jan 8
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
globenewswire.com · Sep 17
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
globenewswire.com · Sep 16
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
globenewswire.com · Sep 16
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
globenewswire.com · Jun 16
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
globenewswire.com · Jun 13
AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
globenewswire.com · Apr 28
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
globenewswire.com · Apr 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.